During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells

Clin Immunol Immunopathol. 1995 Oct;77(1):33-41. doi: 10.1016/0090-1229(95)90134-5.

Abstract

Three-color automated flow cytometry was carried out on peripheral blood CD4+ and CD8+ T-lymphocytes of 42 HIV-positive patients using tri-color anti-CD4 or anti-CD8, phycoerythrin-anti-CD38, and fluorescein-anti-HLA-DR, mAbs to elucidate further the T-cell activation hypothesis recently proposed to explain CD4+ T-cell abnormalities observed during HIV infection. CD4+ CD38+ T-cells constituted the major part of circulating CD4+ T-cells in HIV-infected patients and their HLA-DR molecule positivity increased as their disease progressed. The level of CD38 and HLA-DR expression on CD4+ T-cells was positively correlated to that of CD8+ T-cells and to the level of beta 2-microglobulin. Next, to determine whether CD38 expression was associated with a selective expansion or deletion of V beta gene-defined subsets, we compared the V beta gene frequencies between CD38+ and CD38- T-cells from HIV-infected CDC stage II patients using 13 mAbs specific to V beta families. While selective expansion of certain V beta families was observed in CD4+ and CD8+ T-cells the T-cell receptor V beta subset distribution was similar among CD38+ and CD38-, CD4+ and CD8+ T-cells, suggesting that CD38+ expression was either independent of an HIV-encoded antigen-driven process or rather indicative of T-cell immaturity. It is proposed that the phenotype of circulating CD4+ and CD8+ T-cells of HIV-infected patients is a feature of two different mechanisms: (i) an in vitro activation state responsible for increased DR expression and selective expansion of V beta gene-defined subsets, and (ii) T-cell immaturity due to an increased turnover of these cells and accounting for increased CD38 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase
  • ADP-ribosyl Cyclase 1
  • Acquired Immunodeficiency Syndrome / immunology*
  • Acquired Immunodeficiency Syndrome / pathology
  • Adult
  • Antigens, CD*
  • Antigens, Differentiation / metabolism*
  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • CD4-CD8 Ratio
  • CD4-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / immunology
  • Female
  • Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
  • HLA-DR Antigens / metabolism*
  • Humans
  • Lymphocyte Activation
  • Male
  • Membrane Glycoproteins
  • Middle Aged
  • N-Glycosyl Hydrolases / metabolism*
  • Receptors, Antigen, T-Cell, alpha-beta / genetics*
  • T-Lymphocyte Subsets / immunology*
  • Zidovudine / therapeutic use
  • beta 2-Microglobulin / metabolism

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • Antiviral Agents
  • HLA-DR Antigens
  • Membrane Glycoproteins
  • Receptors, Antigen, T-Cell, alpha-beta
  • beta 2-Microglobulin
  • Zidovudine
  • N-Glycosyl Hydrolases
  • ADP-ribosyl Cyclase
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1